Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF, Gaillard S, Wahner Hendrickson AE, Yeku O, Diver E, Gunderson Jackson C, Arend R, Ratner E, Samnotra V, Gupta D, Chung J, Zhang H, Compton N, Baines A, Bacqué E, Liu X, Felicetti B, Konecny GE.
Liu JF, et al. Among authors: gunderson jackson c.
JCO Precis Oncol. 2024 May;8:e2300693. doi: 10.1200/PO.23.00693.
JCO Precis Oncol. 2024.
PMID: 38754056
Free PMC article.
Clinical Trial.